Literature DB >> 33045700

Onset of action of inhaled glucocorticoids on bronchial and alveolar nitric oxide output.

Tuomas Karvonen1, Anna Sepponen-Lavikko2, Kati Holm3, Rüdiger Schultz3,4, Eeva Moilanen5, Lauri Lehtimäki1,4.   

Abstract

Fractional exhaled nitric oxide (FENO) is a marker of airway inflammation. Measuring FENO at multiple flow rates enables calculation of NO parameters: bronchial NO output (J awNO), bronchial wall (C awNO) and alveolar (C ANO) NO concentrations, and bronchial diffusion factor of NO (D awNO). FENO is known to rapidly reduce after the commencement of inhaled corticosteroid (ICS) treatment. However, little is known on the effect of ICS on the other NO parameters. We assessed (1) the onset of action of ICS treatment on the NO parameters and (2) whether the changes in bronchial NO output are due to changes in bronchial wall NO concentration or diffusion factor. FENO and other NO parameters were measured at baseline and after 1, 3 and 7 d of treatment with inhaled fluticasone propionate 250 μg b.i.d. in 23 allergic children with a history of asthma-like symptoms. There was a decrease in J awNO (from 680 (244/1791) (median (1st/3rd quartile)) to 357 (165/753) pl s-1, p < 0.001) and FENO50( from 13.8 (7.5/35) to 8.3 (5.36/17.0) ppb, p < 0.001) in 3 d from the first dose of ICS. Also, C awNO seemed to reduce after 3 d (from 171 (89/328) to 79 (54/157) ppb, p = 0.041), while D awNO remained unchanged. Furthermore, C ANO reduced during the 7 d treatment (from 3.0 (2.0/5.0) to 2.3 (1.9/2.6) ppb, p = 0.004). ICS treatment reduced FENO50 and J awNO rapidly and the decline was caused by decreased bronchial wall NO concentration while bronchial NO diffusion factor remained unchanged. These findings suggest that C awNO could be a more specific marker of airway inflammation and treatment response than J awNO or FENO50, which are both determined also by D awNO that seems to be resistant to the treatment with ICS.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33045700     DOI: 10.1088/1752-7163/abc054

Source DB:  PubMed          Journal:  J Breath Res        ISSN: 1752-7155            Impact factor:   3.262


  1 in total

1.  Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment.

Authors:  Tomas Weitoft; Anders Lind; Anders Larsson; Johan Rönnelid; Marieann Högman
Journal:  Sci Rep       Date:  2022-04-20       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.